Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
572.36+2.99 (+0.53%)
At close: 4:00PM EDT
572.00 -0.36 (-0.06%)
After hours: 07:38PM EDT
After hours: 07:38PM EDT
| Previous close | 569.37 |
| Open | 570.03 |
| Bid | 560.00 x 800 |
| Ask | 575.00 x 1100 |
| Day's range | 565.39 - 573.01 |
| 52-week range | 441.00 - 686.62 |
| Volume | 492,958 |
| Avg. volume | 783,581 |
| Market cap | 61.217B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 10.34 |
| EPS (TTM) | 55.38 |
| Earnings date | 04 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 690.00 |
- Motley Fool
Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
- Yahoo Finance Video
Pfizer says vaccine is 90.7% effective in kids aged 5 to 11: BBG
Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
- Zacks
Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study
Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.
© 2021 Verizon Media. All rights reserved.
